Future Directions For PARP Inhibition in Breast Cancer: Where Do We Go from Here?

Download this slideset from a live symposium providing insights into new directions with PARP inhibitors for patients with breast cancer.
Jennifer K. Litton, MD
Lee Schwartzberg, MD, FACP
Format: Microsoft PowerPoint (.ppt)
File Size: 512 KB
Released: December 6, 2018


Jointly provided by National Comprehensive Cancer Network (NCCN) and Clinical Care Options, LLC

Karen Kanefield
Manager CE Accreditation & Program Operations
National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting, PA 19462

215-690-0283 (Fax)
For Clinicians:
For Patients:

This activity is supported by educational grants from
Pfizer Inc.

Related Content

Commentary by Dr. Kevin Kalinsky: Sequencing checkpoint inhibitors and sacituzumab govitecan in advanced TNBC with vs without BRCA mutation, from CCO

Kevin Kalinsky, MD, MS Released: December 23, 2020

Downloadable slideset with key data from the 2020 SABCS Virtual Symposium from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: December 18, 2020

Video of expert discussion on testing HER2, HER3, and TROP2 status and using targeted agents for breast and gastrointestinal cancers, from Clinical Care Options (CCO)

Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Program Director
Axel Grothey Headshot Axel Grothey, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: December 17, 2020 Expired: December 16, 2021

Download this short expert slideset on using immune checkpoint inhibitors and antibody–drug conjugates for early and advanced TNBC, from CCO

Kevin Kalinsky, MD, MS Heather McArthur, MD, MPH Rita Nanda, MD Released: December 16, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.